This expert outsourcing report is a comprehensive look at the pharmaceutical manufacturing landscape for emerging markets in Q2 2026, including analysis of news and trends affecting contract manufacturing organizations (CMOs) and the identification of recent contract service agreements, mergers, acquisitions, and financing among CMOs. It is a critical source for strategic planning efforts and will improve understanding of crucial components of the pharmaceutical value chain that will provide insights into API (biologics and chemical) as well as dose manufacturing and packaging (clinical and commercial) for countries in emerging markets.
Scope
This report gives an important monthly update on the pharmaceutical outsourcing industry, based on analysis from the analyst's experts and our databases covering deals, companies, drugs, financials, news, clinical trials, and more. This report is required reading for:- CMO executives and strategic decision-makers: to improve understanding of the CMO industry and provide a critical input for strategic planning efforts.
- Sourcing and procurement executives in bio/pharmaceutical companies: to improve understanding of crucial components of the supply base that will provide insights for supplier selection and management.
- Investors, advisors, and consultants: they can gain a deeper understanding of the CMO market and important insights for identifying potential investment targets.
Reasons to Buy
- Understand current trends and equip yourself with forward-thinking strategies to navigate challenges and capitalise on emerging trends driving the pharmaceutical manufacturing industry. Use our radar to identify developments and innovations with high impact.
- Discover the latest opportunities and threats in the contract manufacturing industry, based on clinical trials and regulatory decisions.
- Learn about the past quarter’s M&A and financing deals in the manufacturing space.
- Identify the latest contract service agreements.
- Develop your competitor or market intelligence by reading about inspection outcomes and facility investments.
- Stay ahead of disruption with updates on supply chain obstacles and new regulations.
Table of Contents
1 Industry Trends
2 Industry Analysis
3 Value Chain
List of Tables
List of Figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Akeso
- Ajanta Pharma Ltd
- Alchymars ICM SM Pvt Ltd
- Alembic Pharmaceuticals Ltd
- Alkem Laboratories Ltd
- Altruist Biotechnology Ltd
- Altaris
- Anupam Rasayan India Ltd
- Arinna Lifesciences Pvt Ltd
- Aurobindo Pharma Ltd
- Bavarian Nordic AS
- Biodexa Pharmaceuticals PLC
- Bliss GVS Pharma Ltd
- Boehringer Ingelheim Pharmaceuticals
- BrightGene Bio-Medical Technology Co Ltd
- Bristol Myers Squibb
- BYD
- Carbogen Amcis AG
- Charles River Laboratories
- China Chamber of International Commerce
- Cipla Ltd
- Citeline/Informa
- Crystal Pharmatech Co Ltd
- dProtein Pharmaceutical Biotechnology Co Ltd
- Earendil Labs Inc
- Embio Ltd
- Flowchem Pharma Pvt Ltd
- Granules India Ltd
- Hengrui
- Henan Lvyuan Pharmaceutical Co Ltd
- Indoco Remedies Ltd
- Innovent
- Intas Pharmaceuticals Ltd
- Lupin Ltd
- Mabwell Shanghai Bioscience Co Ltd
- Morepen Laboratories Ltd
- NAMSA
- NSG BioLabs
- Orchid Pharma Ltd
- Pfizer
- Porton Pharma Solutions Ltd / Proton Pharma Pvt Ltd
- Quadria Capital Advisors Pvt Ltd
- Rafa Laboratories Co Ltd
- Recipharm Israel
- Rubicon Research Ltd
- Rusan Pharma Ltd
- Sai Life Sciences Ltd
- Samarth Life Sciences Pvt Ltd
- Scinai Immunotherapeutics Ltd
- Scinai Biopharma Services
- Serum Institute of India Pvt Ltd
- Shilpa Medicare Ltd
- Sihuan Pharmaceutical Holdings Group Ltd
- Solara Active Pharma Sciences Ltd
- Solopharm
- Supriya Lifescience Ltd
- Summit Therapeutics
- Sunways India Pvt Ltd
- Syngene International Ltd
- Torrent Pharmaceuticals Ltd
- True North Capital
- Wanbury Ltd
- WuXi AppTec
- WuXi ATU
- WuXi Biologics
- Zhejiang Jiuzhou Pharmaceutical Co Ltd
- Zydus Lifesciences Ltd
